MicroVue™ BAP EIA

The MicroVue BAP EIA provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum.

Product Specifications

Citations	21
Specimen	Serum 20 μL
LLOQ	2 U/L
ULOQ	140 U/L
Assay Time	3.5 hours
Cross Reactivity	Baboon, Cow, Cynomolgous monkey, Dog, Goat, Horse, Rabbit, Rat, Rhesus monkey, Sheep

Technical Documents

Ordering Information

For In Vitro Diagnostic Use.

Catalog Number	8012
Catalog Number (CE)
Size	96 wells/test
Price (USD)	$970.00
Price (EURO)	680,00 €

Request an Order

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	contact-us@quidelortho.com
EU Email	contact-emea@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	The MicroVue BAP EIA provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum.
Size	96 wells/test
Form	96 well plate with 12 eight-well strips in a resealable foil pouch
Specimen	Serum 20 μL
Limit of Detection (LOD)	0.7 U/L
Lower Limit of Quantitation (LLOQ)	2 U/L
Upper Limit of Quantitation (ULOQ)	140 U/L
Intra Assay	3.9–5.8%
Inter Assay	5.0–7.6%
Standards	6
Controls	2
Sample Values	Females (Ages 25–44) 11.6–29.6 U/L, Males (Ages ≥25) 15.0–41.3 U/L
Assay Time	3.5 hours
Cross Reactivity	Baboon, Cow, Cynomolgous monkey, Dog, Goat, Horse, Rabbit, Rat, Rhesus monkey, Sheep
Storage	Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components
Background	BAP is an enzyme produced by osteoblasts, the cells responsible for bone formation. The MicroVue BAP immunoassay provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum as an indicator of osteoblastic activity. Measurement of BAP is intended for use as an aid in the 1) management of postmenopausal osteoporosis and Paget's disease, 2) monitoring of postmenopausal women on hormonal or bisphosphonate therapy, and 3) prediction of skeletal response to hormonal therapy in postmenopausal women.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study	2024	ELISA	Human	Serum	Chronic Kidney Disease
Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity	2024	ELISA	Human	Serum	Metabolic bone disease of prematurity
Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.	2018	ELISA	Cynomolgus Monkey	Serum
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women.	2010	ELISA	Human	Serum
Calcium requirements and metabolism in Chinese-American boys and girls.	2010	ELISA	Human	Serum
Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: a cross-sectional study.	2013	ELISA	Human	Plasma	Women Using Hormonal Contraceptives
Age-related bone turnover markers and osteoporotic risk in native Chinese women.	2014	ELISA	Human	Serum
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.	2014	ELISA	Human	Serum
Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.	2014	ELISA	Human	Serum	Mucopolysaccharidosis Types I, II, and VI in children
Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial.	2014	ELISA	Human	Serum	Cholecalciferol
Ethnic differences in urinary calcium and phosphate excretion between Gambian and British older adults	2015	ELISA	Human	Plasma
Different health behaviours and clinical factors associated with bone mineral density and bone turnover in premenopausal women with and without type 1 diabetes.	2015	ELISA	Human	Serum	Premenopausal Women w/wo Type 1 Diabetes
Higher daily physical activity is associated with higher osteocalcin levels in adolescents.	2015	ELISA	Human	Serum	Obesity, children
Effects of an 8-Month Ashtanga-Based Yoga Intervention on Bone Metabolism in Middle-Aged Premenopausal Women: A Randomized Controlled Study.	2015	ELISA	Human	Serum	Middle-Aged Premenopausal Women
Relationship of serum GDF11 levels with bone mineral density and bone turnover markers in postmenopausal Chinese women.	2016	ELISA	Human	Serum	Postmenopausal women
Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.	2017	ELISA	Human	Serum
Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers.	2019	ELISA	Human	Serum	Chronic Kidney Disease
Selected serum microRNA, abdominal aortic calcification and risk of osteoporotic fracture.	2019	ELISA	Human	Serum
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.	2018	ELISA	Human	Serum
Low-Salt' Bread as an Important Component of a Pragmatic Reduced-Salt Diet for Lowering Blood Pressure in Adults with Elevated Blood Pressure	2019	ELISA	Human	Serum
Vitamin D and Abdominal Aortic Calcification in Older African American Women, the PODA Clinical Trial.	2020	ELISA	Human	Serum	Older African American Women
The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD – the exploratory randomized controlled double-blind ExplorIRON-CKD study	2024	ELISA	Human	Serum	CKD
Effects of combined maternal administration with alpha-ketoglutarate (AKG) and β-hydroxy-β-methylbutyrate (HMB) on prenatal programming of skeletal properties in the offspring.	2012	ELISA	Porcine	Serum

Certificate of Analysis

Showing results for

No results found for